Ongoing efforts to design tumor-selective 4-1BB agonists coupled with pre-clinical studies focused on revealing the detailed cellular and molecular mechanisms by which 4-1BB agonists enhance tumor immunity, alone and in combination with other therapies, predict a significant role for these agents in the future of clinical tumor immunotherapy. This evidence concerns the gene TNFRSF9 and neoplasm.